Tag: Paul Flynn

The below Parliamentary question was asked by Paul Flynn on 2015-11-10.

To ask the Prime Minister, what matters relating to (a) nuclear disarmament and (b) nuclear non-proliferation he discussed with the Prime Minister of India during his visit to London in November 2015.

Mr David Cameron

During Prime Minister Modi’s visit India and the UK agreed a Defence and International Security Partnership that pledged to deepen our dialogue on disarmament and non-proliferation and work towards India’s entry into all Export Control Regimes. India and the UK also released a Joint Statement that welcomed the agreement reached earlier this year on Iran’s nuclear programme, and noted the strong commitment of the international community to its swift and full implementation.

The below Parliamentary question was asked by Paul Flynn on 2015-11-24.

To ask the Secretary of State for Foreign and Commonwealth Affairs, with reference to paragraph 4.79 of the National Security Strategy and the Strategic Defence and Security Review 2015, what steps the Government has taken since 2010 to achieve the long-term goal of a world without nuclear weapons; and what initiatives the Government has taken to date to work with the UK’s international partners to tackle proliferation and to make progress on multilateral nuclear disarmament.

Mr Tobias Ellwood

The UK National Report submitted in February in advance of the Nuclear Non-Proliferation Treaty Review Conference set out steps we have taken to support the goal of a world without nuclear weapons. This includes support to the international monitoring system designed to detect nuclear tests, efforts to build trust and confidence with other Nuclear Weapon States through the P5 process, and initiatives with Norway and the US on how to verify disarmament of nuclear weapons. We have also met our commitment to reduce the number of operationally available warheads to no more than 120. We have worked to strengthen the international non-proliferation regime, most notably through our role in securing an agreement involving strict limits and inspections on Iran’s nuclear programme.

The below Parliamentary question was asked by Paul Flynn on 2015-11-26.

To ask the Secretary of State for Energy and Climate Change, what representations she has received from the Global Commission on the Economy and Climate on the Paris Climate Conference; and whether she has evaluated that Commission’s list of 10 opportunities for economically beneficial climate action.

Andrea Leadsom

My rt. hon. Friend the Secretary of State is aware of the work from the Global Commission on the Economy and Climate, as the UK is one of its commissioning countries. The Secretary of State welcomed the Global Commission’s reports, which underlined that growth and tackling climate change can go hand in hand.

We continue to reflect on the reports’ findings and contribution to the economic debate. It sets out how Governments of countries at different stages of economic development can achieve strong economic performance, improve standards of living, create jobs and reduce poverty, whilst simultaneously helping to reduce the risks of climate change. The reports’ evidence on the potential economic opportunities is a powerful contribution to the clear case for action. It is in this spirit that we strongly recommend all countries to consider its findings.

The below Parliamentary question was asked by Paul Flynn on 2015-12-02.

To ask the Secretary of State for Foreign and Commonwealth Affairs, when he expects that the trial will begin of Michael Misick, former Prime Minister of the Turks and Caicos Islands.

James Duddridge

We expect the trial to start this week.

The below Parliamentary question was asked by Paul Flynn on 2015-12-15.

To ask the Secretary of State for Energy and Climate Change, whether she has reviewed the fitness-for-purpose of the UK Nuclear Industry Malicious Capability Planning Assessment to deal with attacks similar to those carried out recently in Paris and San Bernadino.

Andrea Leadsom

The security of the UK’s civil nuclear sector is of paramount importance to the Government. The Nuclear Industry Malicious Capability Planning Assumptions (NIMCA) provide a common basis for determining the sector’s required protective security posture. It is reviewed by DECC, the Office for Nuclear Regulation (ONR), and industry representatives on an annual basis. To ensure that the NIMCA assumptions remain appropriate, these annual reviews are supplemented with assessments of threat information provided by the police and the intelligence agencies on an ongoing basis. Additionally, the ONR maintains a permanent presence within the Joint Terrorism Analysis Centre, which guarantees the fastest possible identification and notification of intelligence that might indicate changes to present and foreseeable threats to civil nuclear sites.

The below Parliamentary question was asked by Paul Flynn on 2016-01-07.

To ask the Secretary of State for Foreign and Commonwealth Affairs, whether he plans to support initiative to the create an independent regional centre for security dialogue in the Middle East.

Mr Tobias Ellwood

A stable and secure Middle East is a key UK priority. We are working with the international community to support those tackling short term conflict and promoting longer-term reform in the region. We believe that regional security initiatives can have an important role to play too.

We are not aware of any specific, new initiatives to create an independent regional centre for security dialogue in the Middle East, at the current time.

The below Parliamentary question was asked by Paul Flynn on 2016-01-20.

To ask the Secretary of State for Foreign and Commonwealth Affairs, what proposal the Government plans to put to the second UN open-ended working group on nuclear disarmament.

Mr Tobias Ellwood

The UK and the four other Non-Proliferation Treaty Nuclear Weapons States voted against the Resolution “Taking forward multilateral nuclear disarmament negotiations” in the UN General Assembly First Committee which established an Open Ended Working Group. The Government believes that productive results can only be ensured through a consensus-based approach that takes into account the wider global security environment.

The below Parliamentary question was asked by Paul Flynn on 2016-02-09.

To ask the Secretary of State for Foreign and Commonwealth Affairs, if he will make an assessment of the effect on employment levels in the Syrian textile industry of the application of sanctions on Syria; and if he will estimate the number of Syrian textile workers and their families who have left Syria due to the loss of employment arising from application of economic sanctions.

Mr Tobias Ellwood

International sanctions restrict the regime’s ability to wage war against the civilian population and pressure the regime to engage in negotiations with the opposition. The UK fully supports EU sanctions against Syria which are rigorously assessed to ensure restrictive measures are targeted and proportionate. We are mindful of the humanitarian impact of sanctions.

There are no EU sanctions specifically on the Syrian textile industry and we are not aware of any direct impact of sanctions on employment levels in the textile industry.

The high number of civilians fleeing Syria is a direct consequence of the regime’s brutal five-year war against the civilian population. The regime has repeatedly employed siege tactics, indiscriminately attacked densely populated areas and targeted civilian infrastructure. Therefore, only by securing a political solution to the Syrian conflict will it be possible to provide stability for Syrian workers and their families, and stop the current levels of people leaving Syria.

The below Parliamentary question was asked by Paul Flynn on 2016-02-23.

To ask the Secretary of State for Business, Innovation and Skills, what assessment he has made of the potential implications for projects supported by State Aid agreements of the UK leaving the EU.

Anna Soubry

The Government’s view is that the UK will be stronger, safer and better off in a reformed European Union.

As required by the EU Referendum Act 2015, the Government is committed to producing clear information, ahead of the Referendum, on: the outcome of the renegotiation, rights and obligations in European Union law, an assessment of alternatives to membership, and the process for leaving.

The below Parliamentary question was asked by Paul Flynn on 2016-03-07.

To ask the Secretary of State for Health, how many instances of adverse reactions have been reported under the Yellow Card Scheme; and what the nature of the reaction reported was in the case of (a) dabigatran, (b) rivaroxaban and (c) apixaban.

George Freeman

Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines through the spontaneous reporting scheme, the Yellow Card Scheme. The scheme collects suspected ADR reports from the whole of the United Kingdom in relation to all medicines and vaccines. Reporting to the Yellow Card Scheme is voluntary for healthcare professionals and members of the public. There is also a legal obligation for pharmaceutical companies to report all serious ADRs for their products that they are aware of.

The table below provides the number of UK suspected spontaneous ADR reports received via the Yellow card Scheme in association with each drug substance as requested.

The information in the table shows the number of UK spontaneous suspected ADR reports in association with Dabigatran, Rivaroxaban and Apixaban up to and including 7 March 2016.

Drug substance	Number of reports
Dabigatran	1,552
Rivaroxaban	3,291
Apixaban	900

A full list of the type and number of reactions, broken down by the reaction term, is publically available for each medicine on the MHRA website. It is important to note that Yellow Card reports are not proof of a side effect occurring due to the medicine but only a suspicion by the reporter that the medicine may have caused the side effect. Yellow Card reports may therefore relate to true side effects of the medicine, or they may be due to coincidental illnesses that would have occurred in the absence of the medicine.

Dabigatran, rivaroxaban and apixaban are anticoagulant medicines used to prevent or treat blood clots. The most commonly reported adverse reaction for all three medicines is gastrointestinal haemorrhage or bleeding, which is in keeping with the known anticoagulant effects of these medicines. Other relatively commonly reported suspected adverse reactions include bleeding at other sites of the body, gastrointestinal symptoms (such as nausea, pain and diarrhoea), anaemia, and rash. These adverse reactions are described in the product information, in both the Patient Information Leaflet for patients and the Summary of Healthcare Products for healthcare professionals.